[go: up one dir, main page]

MX2012013375A - Peptido c pegilado. - Google Patents

Peptido c pegilado.

Info

Publication number
MX2012013375A
MX2012013375A MX2012013375A MX2012013375A MX2012013375A MX 2012013375 A MX2012013375 A MX 2012013375A MX 2012013375 A MX2012013375 A MX 2012013375A MX 2012013375 A MX2012013375 A MX 2012013375A MX 2012013375 A MX2012013375 A MX 2012013375A
Authority
MX
Mexico
Prior art keywords
peptide
pegylated
modified forms
activityin
terminus
Prior art date
Application number
MX2012013375A
Other languages
English (en)
Inventor
James Callaway
Sheri Barrack
Michelle Mazzoni
Original Assignee
Cebix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cebix Inc filed Critical Cebix Inc
Publication of MX2012013375A publication Critical patent/MX2012013375A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a formas modificadas de péptido C y métodos para su uso. En un aspecto, las formas modificadas del péptido C comprenden derivados de péptido C PEGilados que comprenden al menos un grupo PEG unido al extremo N, que exhiben actividad farmacocinética y biológica superior in vivo.
MX2012013375A 2010-05-17 2011-05-17 Peptido c pegilado. MX2012013375A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34529310P 2010-05-17 2010-05-17
US201161448402P 2011-03-02 2011-03-02
PCT/US2011/036858 WO2011146518A2 (en) 2010-05-17 2011-05-17 Pegylated c-peptide

Publications (1)

Publication Number Publication Date
MX2012013375A true MX2012013375A (es) 2013-04-11

Family

ID=44992295

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013375A MX2012013375A (es) 2010-05-17 2011-05-17 Peptido c pegilado.

Country Status (9)

Country Link
US (2) US8927488B2 (es)
EP (1) EP2571896A4 (es)
JP (1) JP2013533217A (es)
KR (1) KR20130115086A (es)
CN (1) CN103119055A (es)
CA (1) CA2798518A1 (es)
MX (1) MX2012013375A (es)
NZ (1) NZ603399A (es)
WO (1) WO2011146518A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP4450523A3 (en) * 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
CA2798518A1 (en) 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
WO2013040093A2 (en) * 2011-09-12 2013-03-21 Amunix Operating Inc. Glucagon-like peptide-2 compositions and methods of making and using same
EP2780030A4 (en) * 2011-11-17 2015-11-18 Cebix Ab PEGYLATED C-PEPTIDE
US20130288973A1 (en) * 2011-12-14 2013-10-31 Edmund Burke Decellularized small particle tissue
US9988433B2 (en) * 2013-03-14 2018-06-05 Mosaic Biosciences, Inc. Covalent modification of biological macromolecules
EP2822533B1 (en) 2012-02-02 2021-01-20 Mosaic Biosciences, Inc. Biomaterials for delivery of blood extracts and methods of using same
WO2013148579A1 (en) * 2012-03-29 2013-10-03 Cebix Inc. Pegylated c-peptide
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
CA2918369C (en) * 2013-07-18 2021-06-29 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
WO2015042639A1 (en) * 2013-09-24 2015-04-02 Hospira Adelaide Pty Ltd Method of extracting protein
EP3256167B1 (en) * 2015-02-09 2020-11-11 Mosaic Biosciences, Inc. Degradable thiol-ene polymers and methods of making thereof
HK1246306A1 (zh) * 2015-03-03 2018-09-07 阿瓦隆生物制品有限公司 聚乙二醇化的il-11的组合物和方法
CA2979397A1 (en) 2015-03-12 2016-09-15 Board Of Trustees Of Michigan State University Compositions and methods for measuring c-peptide binding and diagnosing immune-mediated diseases
JP6991569B2 (ja) * 2015-09-18 2022-02-15 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
CN108265044B (zh) * 2016-12-31 2021-05-11 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
WO2018229252A1 (en) 2017-06-16 2018-12-20 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
JP7058857B2 (ja) * 2017-08-30 2022-04-25 クラシエホームプロダクツ株式会社 毛髪タンパク質の水との相互作用測定方法
EP3449935A1 (en) * 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
ES2974289T3 (es) * 2017-09-28 2024-06-26 Univ California Hidrogeles de polipéptidos de complejo poliiónico y utilizaciones de los mismos
KR102612576B1 (ko) * 2017-09-29 2023-12-12 한미약품 주식회사 링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법
HUE066011T2 (hu) * 2017-12-01 2024-07-28 Csl Behring Llc A1AT hematopoietikus sejt átültetése után akut graft versus host betegség fellépése kockázatának csökkentésére
CN118460462A (zh) 2017-12-01 2024-08-09 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
KR102854142B1 (ko) * 2018-05-16 2025-09-04 시에스엘 리미티드 가용성 보체 수용체 1형 변이체 및 이의 용도
EP3628682A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3865179B1 (en) * 2018-10-25 2025-07-23 The University of Osaka Hmgb1 derived peptide for treating or preventing a cartilage disorder
KR20250162948A (ko) 2018-11-15 2025-11-19 퀀텀-에스아이 인코포레이티드 단백질 시퀀싱을 위한 방법 및 조성물
US20220177704A1 (en) * 2019-03-27 2022-06-09 The Regents Of Theuniversity Of California Mixtures of synthetic copolypeptide hydrogels
CN113646323A (zh) 2019-03-29 2021-11-12 日油株式会社 分支型分解性聚乙二醇键合物
US12497508B2 (en) 2019-03-29 2025-12-16 Nof Corporation Branched and degradable polyethylene glycol derivative
KR102456958B1 (ko) 2019-05-14 2022-10-21 강원대학교 산학협력단 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물
CN111939244B (zh) 2019-05-14 2024-08-06 阿莫生命科学有限公司 用于预防或治疗糖尿病并发症的药物组合物
EP4147711A4 (en) * 2020-04-20 2024-04-24 Shionogi & Co., Ltd Formulation containing hmgb1 partial peptide
US12090206B2 (en) 2020-04-23 2024-09-17 The Regents Of The University Of California Compositions comprising tri- and penta-block synthetic copolypeptide hydrogels
US12065466B2 (en) * 2020-05-20 2024-08-20 Quantum-Si Incorporated Methods and compositions for protein sequencing
CN114137094A (zh) * 2020-09-03 2022-03-04 北京渼颜空间生物医药有限公司 一种聚左旋乳酸中有关物质的检测方法
US20220401525A1 (en) * 2021-06-16 2022-12-22 Biocell Technology, Llc Use of collagen compositions for increasing telomere length
CN116554267A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 聚乙二醇修饰的激肽或其变体和药物应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1176158A (en) 1981-08-27 1984-10-16 Ronald E. Chance Pharmaceutical formulations comprising human insulin and human c-peptide
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
FR2686759B1 (fr) 1992-01-29 1994-04-22 Sgs Thomson Microelectronics Dispositif de regulation de puissance pour un haut-parleur de poste de telephone pendant une sonnerie .
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US6410511B2 (en) * 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
GB9716790D0 (en) 1997-08-07 1997-10-15 Creative Peptides Sweden Ab Recombinant DNA molecules comprising multimeric copies of a gene sequence and expression thereof
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
ATE268609T1 (de) 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
RU2242244C2 (ru) 1999-01-14 2004-12-20 Амилин Фармасьютикалз, Инк. Новые композиции агонистов эксендина и способы их введения
US6376470B1 (en) 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
AU781839B2 (en) 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
GB0022342D0 (en) 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
DE10055857A1 (de) 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
DE10055742B4 (de) 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7265186B2 (en) 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
MY127575A (en) 2001-09-07 2006-12-29 Biocon Ltd Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
AU2002352524B2 (en) * 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
JP2005525302A (ja) * 2001-11-20 2005-08-25 ファルマシア・コーポレーション 化学的に修飾されたヒト成長ホルモンコンジュゲート
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
EA200500475A1 (ru) 2002-09-09 2005-10-27 Нектар Терапеутикс Ал, Корпорейшн Водорастворимые полимерные алканалы
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US7432330B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
CN1747748B (zh) 2003-05-23 2011-01-19 尼克塔治疗公司 具有特定原子排列的聚合物衍生物
US20050074425A1 (en) 2003-07-02 2005-04-07 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
BRPI0414017B8 (pt) 2003-09-17 2021-05-25 Nektar Therapeutics Al Corp pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços.
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
US7304041B2 (en) * 2004-04-22 2007-12-04 Regado Biosciences, Inc. Modulators of coagulation factors
WO2005107815A2 (en) 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Polymer derivatives comprising an imide branching point
WO2005108463A2 (en) 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Branched polyethylen glycol derivates comprising an acetal or ketal branching point
GB0412174D0 (en) * 2004-06-01 2004-06-30 Creative Peptides Sweden Ab Degradation-resistant analogues of pro-insulin c-peptide
EP1850878A2 (en) * 2005-02-10 2007-11-07 Novo Nordisk A/S C-terminally pegylated growth hormones
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
WO2007011802A1 (en) 2005-07-18 2007-01-25 Nektar Therapeutics Al, Corporation Method for preparing branched functionalized polymers using branched polyol cores
GB0601950D0 (en) 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
JP4261531B2 (ja) 2005-09-06 2009-04-30 株式会社Ｎｒｌファーマ ラクトフェリン複合体及びその製造方法
US8299026B2 (en) 2006-07-25 2012-10-30 Lipoxen Technologies Limited Derivatisation of erythropoietin (EPO)
WO2008015099A2 (en) * 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
RU2007137048A (ru) * 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) Лекарственное средство для лечения и предупреждения осложнений при сахарном диабете
WO2009117410A2 (en) 2008-03-17 2009-09-24 Board Of Regents, The University Of Texas System Formation of nanostructured particles of poorly water soluble drugs and recovery by mechanical techniques
US20110165112A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of c-peptides
WO2010033240A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
WO2011081915A2 (en) 2009-12-15 2011-07-07 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
CA2798518A1 (en) 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide

Also Published As

Publication number Publication date
US8927488B2 (en) 2015-01-06
US20120220542A1 (en) 2012-08-30
US20120178676A1 (en) 2012-07-12
US8691755B2 (en) 2014-04-08
KR20130115086A (ko) 2013-10-21
NZ603399A (en) 2014-09-26
CA2798518A1 (en) 2011-11-24
CN103119055A (zh) 2013-05-22
WO2011146518A2 (en) 2011-11-24
WO2011146518A3 (en) 2012-03-08
EP2571896A2 (en) 2013-03-27
EP2571896A4 (en) 2014-01-08
JP2013533217A (ja) 2013-08-22
WO2011146518A9 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
MX2012013375A (es) Peptido c pegilado.
JO3026B1 (ar) مستضادات ببتيد شبيه الجلوكاجون - 2
SMT201600216B (it) Ottaidropirrolo[3,4.c]pirroli disostituiti come modulatori del recettore di orexina
WO2013006953A8 (en) Genes and proteins for alkanoyl-coa synthesis
WO2012090150A3 (en) New cell-penetrating peptides and uses thereof
MX338187B (es) Confiterias basadas en proteínas de guisante.
IL219865A0 (en) Acid salt forms of polymer-drug conjugates, compositions comprising the same, methods of producing the same and uses thereof
IT1395519B1 (it) Pezzo composito, nonche' impiego del pezzo composito
ZA201205103B (en) Pharmaceutical composition comprising oligopeptides,preferably cilengitide
ZA201208076B (en) Improvements in or relating to scanning ophthalmoscopes
ZA201200370B (en) Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
MY169650A (en) Crystalline recombinant interferon with altered spatial configuration,three-dimensional structure and uses thereof
WO2011034659A3 (en) Advantageous mu-opiate receptor peptide compounds
GB201220630D0 (en) Kissorphin peptides for use in the treatment of alzheimer's disease, creutzfeldtjakob disease or diabetes mellitus
ZA201201835B (en) 2-amino-3-methyl-hex-5-enoic acid and its use in the production of peptides such as bacitracins
IT1403778B1 (it) Veicolo trainato, particolarmente atto all'impiego agricolo o forestale
AP2011006040A0 (en) Extracellular plant ferredoxin-like protein and uses thereof.
Szulc et al. Clair de lune: mélodie/musique de Joseph Szulc; poésie de Paul Verlaine.
SAITO Take it easy!
斉藤美佳子 Take it easy!
BRPI1014211A2 (pt) "composição."
Gupta Degree M. Sc.--University of Toronto, 2009.
IN2012DN03074A (es)
MX2012004727A (es) Agonistas peptidicos del glp-2.
Bargiel Trio Nr. 3, B dur, Op. 37/Bargiel.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal